LeadStory

CNBC

Sarepta's gene therapy medicine kills patient

CNBC · 19 days ago
CNBC
CNBC
19 days ago

Sarepta Therapeutics has halted distribution of its gene therapy, Levitas, for advanced Duchenne muscular dystrophy patients after a second patient died from liver failure.

BreakdownGenerated by LeadStory AI
  • A second patient has died after receiving Sarepta's gene therapy for Duchenne muscular dystrophy. 4s
  • Both deceased patients were teenagers who could no longer walk, a group recently included in the therapy's approval. 34s
  • The FDA had controversially expanded Levitas' approval to nearly all Duchenne patients last year. 45s
  • Sarepta has halted shipments of the therapy for advanced patients and is reviewing safety protocols. 1m 1s
  • Sarepta has suspended its 2025 financial guidance and its stock has dropped sharply. 1m 7s
HealthBusinessMedical Research